| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D475-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-525 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D475-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2008-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2010-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2010516683-A |
| titleOfInvention |
Compositions and methods for reducing side effects and toxicity by administering methotrexate as an orotic acid derivative |
| abstract |
The present invention relates to the field of chemically reconstituting antimetabolite agents with low oral bioavailability and known to cause tissue toxicity as a side effect by producing their orotic acid derivatives. More particularly, with respect to orotate derivatives of methotrexate and trimetrexate, these may improve oral bioavailability and clearance compared to currently used methotrexate and trimetrexate formulations. It turns out. The present invention provides methotrexate orotate having the structural formula shown below. [Selection] Figure 1 |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014513682-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015042270-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014196324-A |
| priorityDate |
2007-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |